| 2025-11-13 |
详情>>
股本变动：
变动后总股本5428.31万股
|
| 2025-11-13 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.21美元,归母净利润-9579.9万美元,同比去年增长58.04%
|
| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘后发布财报
|
| 2025-08-14 |
详情>>
业绩披露：
2025年中报每股收益-1.88美元,归母净利润-7225.8万美元,同比去年增长-49.55%
|
| 2025-06-09 |
详情>>
内部人交易：
RIGGS RORY B共交易2笔
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-1.34美元,归母净利润-4688.6万美元,同比去年增长-100.07%
|
| 2025-04-10 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to our Board of Directors, each to serve until the next annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal;
2.To approve, on an advisory basis, the compensation of Cibus, Inc.’s Named Executive Officers;
3.To ratify the appointment by the Audit Committee of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2025;
4.To approve the adoption of the Cibus, Inc. 2025 Employee Stock Purchase Plan;
5.To approve, in accordance with Nasdaq Listing Rule 5635(d), the issuance of up to 9,040,000 shares of Class A common stock issuable upon the exercise of outstanding common warrants issued pursuant to those certain Securities Purchase Agreements, each dated January 21, 2025, by and among the Company and the purchasers party thereto (the “Stock Issuance Proposal”);
6.To approve, in accordance with Nasdaq Listing Rule 5635(c), the repricing of certain existing warrants of the Company held by Rory Riggs, Cibus, Inc.’s Board Chairman and former Chief Executive Officer (the “Warrant Repricing Proposal”);
7.To approve, in accordance with Nasdaq Listing Rule 5635(b), the issuance of shares of Class A common stock upon the potential future exercise of certain outstanding warrants held by Rory Riggs, Cibus, Inc.’s Chairman and former Chief Executive Officer, that would be deemed to be a “change of control” of the Company within the meaning of Nasdaq Listing Rule 5635(b) (the “Deemed Change of Control Proposal”).
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-10.83美元,归母净利润-2.51亿美元,同比去年增长6.07%
|
| 2024-12-20 |
复牌提示：
2024-12-19 12:48:04 停牌，复牌日期 2024-12-19 12:58:04
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-10.33美元,归母净利润-2.28亿美元,同比去年增长-351.94%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-2.26美元,归母净利润-4831.8万美元,同比去年增长-100.62%
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-1.12美元,归母净利润-2343.5万美元,同比去年增长-334.46%
|
| 2024-04-19 |
股东大会：
将于2024-05-30召开股东大会
会议内容 ▼▲
- 1.To elect six directors to our Board of Directors, each to serve until the next annual meeting of stockholders and until his successor has been elected and qualified, or until his earlier death, resignation, or removal;
2.To approve, on an advisory basis, the compensation of Cibus, Inc.’s Named Executive Officers;
3.To ratify the appointment by the Audit Committee of BDO USA, P.C. as our independent registered public accounting firm for the year ending December 31, 2024.
|
| 2024-03-21 |
详情>>
业绩披露：
2023年年报每股收益-25.95美元,归母净利润-2.68亿美元,同比去年增长-1484.44%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-6.33美元,归母净利润-5051.3万美元,同比去年增长-259.42%
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-6.73美元,归母净利润-2408.4万美元,同比去年增长-197.19%
|
| 2023-05-19 |
详情>>
拆分方案：
每5.0000合并分成1.0000股
|
| 2023-04-25 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2023-03-22 |
股东大会：
将于2023-05-02召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors to our Board of Directors, each to serve a three-year term and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal;
2.To approve, on an advisory basis, the compensation of Calyxt, Inc.’s Named Executive Officers;
3.To approve, on an advisory basis, the frequency of future votes to approve the compensation of Calyxt, Inc.’s Named Executive Officers;
4.To ratify the appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023.
|
| 2022-04-19 |
股东大会：
将于2022-06-01召开股东大会
会议内容 ▼▲
- 1.To elect eight directors to our Board of Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal;
2.To ratify the appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
3.To approve an amendment to our amended and restated certificate of incorporation to effect a reverse stock split of the Company’s shares of Common Stock at a ratio not less than 2-to-1 and not greater than 10-to-1, with the exact ratio to be set within that range at the discretion of our Board of Directors before April 1, 2024 without further approval or authorization of our stockholders (the “Reverse Stock Split”);
4.Stockholders will also act on such other business and matters or proposals as may properly come before the Annual Meeting.
|
| 2021-04-06 |
股东大会：
将于2021-05-18召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to our Board of Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.Approval of the Amendment to the Calyxt, Inc. 2017 Omnibus Incentive Plan;
|
| 2021-03-15 |
热点提醒：
美股今天进入夏令时交易，盘前交易开始时间提前至北京时间16：00
|
| 2020-04-09 |
股东大会：
将于2020-05-19召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to our Board of Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.To act on such other business and matters or proposals as may properly come before the Annual Meeting.
|
| 2019-04-22 |
股东大会：
将于2019-05-17召开股东大会
会议内容 ▼▲
- 1.To elect seven directors to our Board of Directors, all of whom are currently serving on our Board of Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.To act on such other business and matters or proposals as may properly come before the Annual Meeting.
|
| 2018-04-19 |
股东大会：
将于2018-05-24召开股东大会
会议内容 ▼▲
- 1.To elect five directors to our Board of Directors, all of whom are currently serving on our Board of Directors, each to serve until the next annual meeting of stockholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation or removal;
2.To ratify the expected appointment by the Audit Committee of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018, subject to approval by the shareholders of Cellectis S.A. (“Cellectis”) at the Cellectis annual general meeting of the appointment by Cellectis of Ernst & Young LLP as independent registered accounting firm for Cellectis and its subsidiaries;
3.To act on such other business and matters or proposals as may properly come before the Annual Meeting.
|